MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
"Triple Helix" Innovation Model
3. Triple Helix _ Dynamics
*Driving Forces: Triple Helix _ Translation, Commercialization, Technology Transfer, SBIR/STTR, OTA, NonTraditional / New Business Models
Triple Helix: Regional Innovation Clusters (RIC)s
Intermediaries: Triple Helix Regional Innovation Clusters (RIC)s
RICS (Regional Innovation Clusters) - Medical, Life Sciences & Emerging Technology Hotspots
*Industry: Research Triangle, North Carolina
IMMvention Therapeutix
Organization & Developments: IMMvention Therapeutix
Parents
IMMvention Therapeutix
Children
*Illness-modifying therapies inhibit inflammation caused by inflammasomes
*Proprietary technology that delivers innate immunomodulatory drugs to immune cells
*Small molecule pan-inflammasome inhibitors to improve clinical outcomes in sickle cell disease.
*The company has discovered a series of small molecule BACH1 inhibitors/Nrf2 activators. Activation of the Nrf2 pathway achieves induction of fetal-hemoglobin, anti-oxidative stress, and anti-inflammatory pathways to ameliorate the underlying pathophysiology of many diseases.
*The company’s mission is to develop oral globally accessible therapeutics to address unmet medical needs in hemoglobinopathies (including sickle cell disease and beta-thalassemia), cardiometabolic, renal, and neuroinflammatory diseases caused by dysregulation of multiple pathways.
2025: IMMvention Therapeutix enters collaboration with Novo Nordisk for sickle cell disease therapies
2025: IMMvention Therapeutix Enters Strategic Collaboration with Novo Nordisk to Develop Oral Therapies for Sickle Cell Disease and Other Chronic Diseases
Jumps
Finance & Acquisition: IMMvention Therapeutix
Key People: IMMvention Therapeutix